Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion

BACKGROUND: Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8(+) T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal target to deliver antigens. cDC1s uniquely express XCR1, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Gall, Camille, Cammarata, Anna, de Haas, Lukas, Ramos-Tomillero, Iván, Cuenca-Escalona, Jorge, Schouren, Kayleigh, Wijfjes, Zacharias, Becker, Anouk M D, Bödder, Johanna, Dölen, Yusuf, de Vries, I Jolanda M, Figdor, Carl G, Flórez-Grau, Georgina, Verdoes, Martijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014073/
https://www.ncbi.nlm.nih.gov/pubmed/35428705
http://dx.doi.org/10.1136/jitc-2021-004309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014073/
https://www.ncbi.nlm.nih.gov/pubmed/35428705
http://dx.doi.org/10.1136/jitc-2021-004309

Ejemplares similares